financetom
Business
financetom
/
Business
/
French tycoon Xavier Niel explores buyout bid for Millicom
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
French tycoon Xavier Niel explores buyout bid for Millicom
May 23, 2024 9:54 AM

May 23 (Reuters) - French billionaire Xavier Niel is

considering buying out telecom firm Millicom International

Cellular S.A., his investment vehicle Atlas

Investissement said on Thursday.

The company is exploring financing options to support an

offer price of $24 per common share, Atlas said.

Niel, the founder and owner of French telecom provider

Iliad, is the top shareholder of Millicom, which provides

telecom services in Latin America through its TIGO brand.

Atlas Investissement, a wholly-owned unit of Neil's NJJ

Holding, owns a 29% stake in Millicom, according to LSEG data.

Niel's potential move was first reported by Bloomberg News,

which said that the company's recent share price increases could

make it more difficult to finalize a deal.

U.S.-listed shares of Millicom gained about 33%

this year, giving the company a market value of more than $4

billion as of last close.

The Luxembourg-based telecom firm was in talks with Apollo

Global Management ( APO ) and Claure Group about a potential bid

for the company last year.

Niel increased his stake in Millicom amid those discussions,

which analysts considered as a strategic investment that would

pose additional hurdles to the Apollo deal.

The deal talks were terminated in June last year.

Niel has telecoms investments in nine countries in Europe

with nearly 50 million active subscribers combined and more than

10 billion euros of revenues, Atlas said.

Atlas Investissement said it was independent of Iliad Group

and Iliad Holding.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kian-Backed SPATCO Energy Solutions Continues National Expansion with Acquisition of Excell Fueling Systems
Kian-Backed SPATCO Energy Solutions Continues National Expansion with Acquisition of Excell Fueling Systems
Sep 10, 2025
The acquisition adds commercial services to SPATCO’s Texas portfolio, rounding out the platform’s comprehensive suite of services in the state ATLANTA & CHARLOTTE, N.C.--(BUSINESS WIRE)-- Kian Capital-backed SPATCO Energy Solutions (“SPATCO”), a forward-thinking provider of innovative, turnkey infrastructure services solutions to the petroleum, environmental and EV market segments, has completed the acquisition of Excell Fueling Systems (“Excell”). This marks...
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Sep 10, 2025
ZURICH and NESS ZIONA, Israel, Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSPW) (NLS), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and Kadimastem Ltd. ( KMSTF ) (Kadimastem ( KMSTF )), an advanced clinical-stage cell therapy company progressing treatments for neurodegenerative diseases and diabetes, today announced that the U.S. Securities and Exchange Commission (the...
Form 8.3 - Dowlais Group PLC
Form 8.3 - Dowlais Group PLC
Sep 10, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
Sep 10, 2025
Adjournment to provide time for continued discussions regarding possible revised financial terms of transaction with XenoTherapeutics SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 10, 2025 /PRNewswire/ -- ESSA Pharma Inc. (ESSA, or the Company) today announced that the Board of Directors of the Company has approved an adjournment of the special meeting of the holders of common shares of the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved